Cerenis Therapeutics Share Price CINNOBER BOAT
Equities
0RAG
FR0012616852
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% |
|
-.--% | -.--% |
07-01 | Abionyx Pharma: successful capital increase | CF |
06-14 | Abionyx: positive response from FDA, share price rises | CF |
Sales 2024 * | 4.6M 4.99M 389M | Sales 2025 * | 7.1M 7.7M 600M | Capitalization | 39.48M 42.81M 3.33B |
---|---|---|---|---|---|
Net income 2024 * | -6M -6.51M -507M | Net income 2025 * | -9M -9.76M -760M | EV / Sales 2024 * | 8.19 x |
Net cash position 2024 * | 1.8M 1.95M 152M | Net Debt 2025 * | 200K 217K 16.89M | EV / Sales 2025 * | 5.59 x |
P/E ratio 2024 * |
-7.21
x | P/E ratio 2025 * |
-5.84
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 64.85% |
Managers | Title | Age | Since |
---|---|---|---|
Cyrille Tupin
CEO | Chief Executive Officer | 48 | 31/12/06 |
Director of Finance/CFO | - | 30/04/08 | |
Renee Benghozi
CTO | Chief Tech/Sci/R&D Officer | - | 08/02/15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Olivier Martinez
BRD | Director/Board Member | 54 | - |
Christian Chavy
BRD | Director/Board Member | 75 | 05/02/15 |
Cyrille Tupin
CEO | Chief Executive Officer | 48 | 31/12/06 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+16.61% | 122B | |
+17.75% | 112B | |
-24.11% | 19.33B | |
-17.94% | 16.17B | |
-18.47% | 15.6B | |
-47.75% | 14.65B | |
+57.35% | 14.34B | |
+5.62% | 14B | |
+125.88% | 11.29B |
- Stock Market
- Equities
- ABNX Stock
- 0RAG Stock